Biocytogen Pharmaceuticals Co. Ltd. subsidiary Eucure Biopharma Co. Ltd. has formed a partnership with Syncromune Inc. to combine Eucure’s YH-002 and two other active ingredients with Syncromune’s Syncrovax platform technology in a deal the partners said could be worth “hundreds of millions of U.S. dollars,” including an up-front cash payment of undisclosed value.
Radiopharm Theranostics Ltd.’s phase II F-18 Pivalate positron emission tomography trial in brain metastases saw positive results with high uptake regardless of the origin of primary tumors, showing that Pivalate could be used to monitor brain metastases.
Jazz Pharmaceuticals plc in-licensed regional rights to Zymeworks Inc.’s HER2- targeted bispecific antibody zanidatamab in a deal potentially worth $1.76 billion, plus royalties. Jazz wants to expand its oncology portfolio with the deal, which covers the U.S., Europe, Japan and all other territories except Asia Pacific markets previously licensed by Zymeworks to Beigene Ltd.
Jacobio Pharmaceuticals Co. Ltd. has identified new stimulator of interferon genes protein (STING; TMEM173) agonists reported to be useful for the treatment of cancer.
The Centro Nacional de Investigaciones Oncológicas Carlos III (CNIO) has presented new imidazo[1,2-b]pyridazine-based tricyclic compounds acting as serine/threonine-protein kinase haspin (GSG2) inhibitors and reported to be useful for the treatment of cancer.
Surge Therapeutics Inc. landed $26 million in funding through a series A fundraising round to accelerate development of its intraoperative immunotherapy hydrogel.
Cascination AG reported the first thermal ablation of liver tumors to be performed in France using its CT-guided stereotactic planning and navigation system, CAS-One IR. The technology was used at Dijon Bourgogne University Hospital, where a dozen procedures have been carried out in the Department of Diagnostic and Therapeutic Radiology.
PT Etana Biotechnologies Indonesia secured a series B financing of undisclosed value, led by Chinese investors that include Jack Ma’s Yunfeng Capital and Highlight Capital. The funds will be used to strengthen the company's pipeline and to expand its local manufacturing capacity.
RSS
